Plain-English translation of NCT06045091 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-phase trial is testing a new treatment called human BCMA targeted CAR-NK cells for people with multiple myeloma or plasma cell leukemia that has stopped responding to previous treatments. The treatment uses your own immune cells that have been modified in the laboratory to recognize and attack cancer cells. You would receive two injections of these cells, given one week apart.
Many patients with advanced multiple myeloma or plasma cell leukemia run out of effective treatment options after their cancer stops responding to standard drugs. This trial is exploring whether this new cell-based therapy could offer hope for people in that difficult situation.
You likely qualify if…
You likely don't qualify if…
You would first undergo blood tests, imaging scans, and heart tests to confirm you qualify. Then you would receive chemotherapy to prepare your body for the new treatment. You would receive two injections of the engineered immune cells—one on day 0 and another on day 7. Some study procedures may involve hospitalization, and you would be closely monitored afterward for side effects and how well the treatment works.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China